Evidence map›Paper›PMID 8972219›Full record

ArticleMolecular and cellular biology1997

Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor.

Q Wang, G P Zambetti, D P Suttle

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 155 citations in OpenAlex.

  1. Using different zebrafish models to explore liver regeneration.Frontiers in cell and developmental biology · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. 3,6-Disubstituted 1,2,4-Triazolo[3,4-OncoTargets and therapy · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Q WangDepartment of Pharmacology, College of Medicine, University of Tennessee, Memphis 38163, USA.
G P Zambetti
D P Suttle
University of Tennessee Health Science Center · USSt. Jude Children's Research Hospital · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
MUTANT P53 GAIN OF FUNCTION IN TURMORIGENISISR01CA063230 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI ZAMBETTI, GERARD PAUL · 1995 to 2007
$2.3M
TOPOISOMERASE II - GENE REGULATION AND DRUG RESISTANCER01CA047941 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SUTTLE, DALE P · 1989 to 1999
–
NCI NIH HHS 5P30-CA21765NCI NIH HHS CA47941NCI NIH HHS CA63230
6 · The paper itself

Abstract

DNA topoisomerase II (topo II) is an essential nuclear enzyme involved in major cellular functions such as DNA replication, transcription, recombination, and mitosis. While an elevated level of topo II alpha is associated with cell proliferation, wild-type (wt) p53 inhibits the expression of various growth-stimulatory genes. To determine if p53 downregulates topo II alpha gene expression, a murine cell line, (10)1val, that expresses a temperature-sensitive p53 was utilized. The (10)1val cells had significantly lower levels of topo II alpha mRNA and protein following incubation for 24 h at 32 degrees C (p53 with wt conformation) than at 39 degrees C (p53 with mutant conformation). The effect of p53 on the human topo II alpha gene promoter was determined by using luciferase reporter plasmids containing varying lengths of the topo II alpha promoter transiently cotransfected into p53-deficient (10)1 cells together with wt or mutant p53 expression plasmids. Transcription from the full-length (bp -557 to +90) topo II alpha promoter was decreased 15-fold by wt p53 in a concentration-dependent manner, whereas mutant p53 exerted much weaker inhibition. Consecutive deletion of the five inverted CCAAT elements (ICEs) from the topo II alpha promoter reduced both the basal promoter activity and wt p53-induced suppression. Transcription of the minimal promoter (-32 to +90), which contains no ICE, was slightly stimulated by wt or mutant p53 expression. When point mutations were introduced into the most proximal ICE (-68), the inhibitory effect of wt p53 was alleviated and stimulation of topo II alpha expression resulted. Our study suggests that wt p53 functions as a transcriptional repressor of topo II alpha gene expression, possibly through a functional interaction with specific ICEs. Inactivation of wt p53 may reduce normal regulatory suppression of topo II alpha and contribute to abortive cell cycle checkpoints, accelerated cell proliferation, and alterations in genomic stability associated with neoplasia.

Indexed as

DNA Topoisomerases, Type IIAnimalsAntigens, NeoplasmCell LineDNA-Binding ProteinsDNA, RecombinantGene Expression Regulation, EnzymologicGenes, p53HumansIsoenzymesMiceMutationPromoter Regions, GeneticRNA, MessengerTranscription, GeneticTransfectionAntigens, NeoplasmDNA-Binding ProteinsDNA, RecombinantDNA Topoisomerases, Type IIIsoenzymesRNA, MessengerTumor Suppressor Protein p53

Identifiers

PMID8972219
PMCPMC231763
OpenAlexW2117350062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.